Approval to commence dosing 3rd cohort of ISLA-101 SAD study
Filed with ASX · · 2 pages · English
Island Pharmaceuticals Ltd on 6ix
Story so far
Earlier from Island Pharmaceuticals
- R&D Tax Incentive loan facility secured with Radium Capital
- Second cohort dosed in ISLA-101 Single Ascending Dose study
- Island doses first cohort in ISLA-101 clinical trial
- Screening commences for ISLA-101 Single Ascending Dose Study
- Island receives R&D tax refund for FY2023
Later from Island Pharmaceuticals
- Third cohort dosed in ISLA-101 Single Ascending Dose study
- Quarterly Activity Report and Appendix 4C
- Dosing complete in ISLA-101 SAD study
- Island investor presentation
- $1.95million Fully Underwritten Rights Issue
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals